课题基金 / 基金详情

A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD

A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD
人类唐氏综合症和 DS-AD 分子细胞病理学的新方法
批准号:
9291367
负责人:
JEANNE Bentley LAWRENCE
金额:
$41.93万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-12 至 2022-05-31
关键词:
AffectAlzheimer&aposs DiseaseAreaBiological AssayBiologyCRISPR/Cas technologyCell Differentiation processCell LineageCell physiologyCellsCellular MorphologyCellular StructuresCellular biologyChildChromosomesChromosomes, Human, Pair 21CiliaCodeCoupledDefectDementiaDendritic SpinesDetectionDevelopmentDevelopmental Delay DisordersDevelopmental DisabilitiesDiseaseDown SyndromeEquilibriumFemaleFoundationsFutureGene ExpressionGenesGeneticGenetic TranscriptionGenomeHumanHuman PathologyImmuneIn VitroIndividualLeadMedicalMessenger RNAMethodsMicroRNAsMitochondriaMolecularMolecular ProfilingMorphologyMyeloproliferative diseaseNerve DegenerationNeural CrestNeurobiologyNeurofibrillary TanglesNeurogliaNeurologicNeuronal DifferentiationNeuronsPathologyPathway interactionsPatientsPhenotypePopulationPreclinical Drug EvaluationPresenile Alzheimer DementiaProteinsPublishingRNARNA InterferenceRegulationResearchResearch PersonnelRiskSenile PlaquesStem cellsSyndromeSystemTechnologyTestingTimeTrisomyUndifferentiatedUntranslated RNAVariantWorkX ChromosomeX Inactivationbasebeta-site APP cleaving enzyme 1cell typecellular pathologycognitive disabilitycongenital heart disorderdisease phenotypedrug developmentdrug testinggene therapygenome editinggenome-wideimprovedinduced pluripotent stem cellinsightleukemiamigrationnano-stringnerve stem cellneurodevelopmentneurogenesisnovelnovel strategiesoverexpressionpre-clinicalrelating to nervous systemresearch clinical testingsuperoxide dismutase 1therapeutic developmenttherapy developmenttooltranscriptometranscriptome sequencing

项目摘要

项目成果

JEANNE Bentley LAWRENCE的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Down Syndrome (DS), or Trisomy 21, is the leading genetic cause of developmental and cognitive disability in children. As individuals with DS live longer, we now realize most develop early-onset Alzheimer Disease (AD). In addition, people with DS have greatly increased risk of congenital heart disease, myeloproliferative disorder and leukemia, as well as immune and other system defects. Hence, understanding how three copies of normal genes on chromosome 21 impacts cell expression profiles and cell phenotypes is important not only for DS, but for conditions that afflict the non-DS population, particularly AD, perhaps the biggest medical challenge of our time. Researchers have sought to identify the transcriptional and phenotypic changes responsible for the various aspects of DS; however, this work is hampered by individual variation as well as the genetic complexity and phenotypic variability of DS. Thus, there is a critical need for better ways to determine specific cellular pathologies and gene pathways which underlie aspects of the syndrome, and to facilitate screening of drugs to correct them. We have recently created and demonstrated such a system and, supported by compelling preliminary results, propose to use it to “dissect” the cellular impact of Trisomy 21, on genome-wide pathways and phenotypes, in undifferentiated pluripotent and in neural DS stem cells. We will capitalize upon this unique system to investigate the most direct effects of Trisomy 21 on genome-wide changes in expression of specific genes and pathways (Aim1), correlate this with specific neural cell phenotypic changes (Aim2), and ultimately examine the contribution of specific Chr21 genes (Aim 3) to DS and AD pathology. Rather than focus on one or more “favored” aspects or hypotheses, we propose an unbiased and broad approach, supported by several collaborators who are leaders in their areas of molecular cell biology and neurobiology. This novel approach has great promise to surmount challenges that have confounded clear understanding of the basic biology of DS, and thus provide the foundation for longer-term translational efforts to treat DS. Greater understanding of genes and cell pathways perturbed in human DS is important for development of drug therapies (for DS and AD), but also has implications for the potential development of “chromosome silencing” or gene therapies. This work also has broad basic impact for understanding genome balance, the coordinated levels of expression for genes throughout the genome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome